BR0317342A - Benzodioxepinas substituìdas - Google Patents

Benzodioxepinas substituìdas

Info

Publication number
BR0317342A
BR0317342A BR0317342-9A BR0317342A BR0317342A BR 0317342 A BR0317342 A BR 0317342A BR 0317342 A BR0317342 A BR 0317342A BR 0317342 A BR0317342 A BR 0317342A
Authority
BR
Brazil
Prior art keywords
benzodioxepines
substituted
receptor
benzodioxepins
solvates
Prior art date
Application number
BR0317342-9A
Other languages
English (en)
Inventor
Timo Heinrich
Henning Boettcher
Kai Schiemann
Guenter Hoelzemann
Christoph Van Amsterdam
Gerd Bartoszyk
Hartmut Greiner
Christoph Seyfried
Michel Brunet
Jean Zeiller
Jean Berthelon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0317342A publication Critical patent/BR0317342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"BENZODIOXEPINAS SUBSTITUìDAS". A presente invenção refere-se a benzodioxepinas de fórmula (I) e sais e solvatos fisiologicamente tolerados das mesmas, em que R¬ 1¬,R¬ 2¬,R¬ 3¬, R¬ 4¬, A, B, a e b possuem os significados indicados na reivindicação 1, que são ligantes dos receptores 5HT1A e/ou receptores 5HT4 com forte inibição simultânea de reabsorção de serotonina. Elas podem ser empregadas para o tratamento e profilaxia de várias doenças.
BR0317342-9A 2002-12-20 2003-11-27 Benzodioxepinas substituìdas BR0317342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02028596 2002-12-20
PCT/EP2003/013373 WO2004058746A1 (de) 2002-12-20 2003-11-27 Substituierte benzdioxepine

Publications (1)

Publication Number Publication Date
BR0317342A true BR0317342A (pt) 2005-11-08

Family

ID=32668730

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317342-9A BR0317342A (pt) 2002-12-20 2003-11-27 Benzodioxepinas substituìdas

Country Status (16)

Country Link
US (1) US7253202B2 (pt)
EP (1) EP1572685B1 (pt)
JP (1) JP4575167B2 (pt)
KR (1) KR20050084438A (pt)
CN (1) CN1729187A (pt)
AR (1) AR042554A1 (pt)
AT (1) ATE350379T1 (pt)
AU (1) AU2003289904B2 (pt)
BR (1) BR0317342A (pt)
CA (1) CA2511021C (pt)
DE (1) DE50306228D1 (pt)
ES (1) ES2280824T3 (pt)
MX (1) MXPA05006433A (pt)
PL (1) PL377325A1 (pt)
WO (1) WO2004058746A1 (pt)
ZA (1) ZA200505786B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227023B2 (en) * 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
PL443018A1 (pl) * 2022-12-01 2024-06-03 Uniwersytet Medyczny W Lublinie Pochodne N-((9-chloro-3,4-dihydro-2H-benzo[b][1,4]dioksepin-7-ylo)metylo)-2-(6-fluoro-1H-indol-3-ylo)etano-1-aminy, sposób ich wytwarzania i zastosowanie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700691A (en) * 1969-06-09 1972-10-24 Frosst & Co Charles E 3,3-disubstituted-3,4-dihydrobenzodioxepins
US3812150A (en) * 1969-06-09 1974-05-21 Frosst & Co 3,3-disubstituted-benzodioxepins
US3944560A (en) * 1972-05-01 1976-03-16 Merck & Co., Inc. 3-Hydroxy-3-(1,2,5-thiadiazolyloxyalkanol)-3,4-dihydro-2H-1,5-benzodioxepin products
GB2007656B (en) 1977-11-05 1982-05-19 Pfizer Ltd Therapeutic agents
DK166779B1 (da) * 1983-12-14 1993-07-12 Takeda Chemical Industries Ltd 1,5-benzoxatiepinderivater eller farmaceutisk acceptable salte deraf, samt farmaceutisk praeparat indeholdende en saadan forbindelse
JP2865341B2 (ja) * 1988-12-28 1999-03-08 サントリー株式会社 ベンゾオキサゼピン誘導体
JP3732554B2 (ja) * 1994-07-07 2006-01-05 旭化成ファーマ株式会社 新規な２，３−ジヒドロベンゾフラン誘導体、その製造方法および用途
WO1996001816A1 (fr) * 1994-07-07 1996-01-25 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau derive de 2,3-dihydrobenzofuranne, son procede de production et son utilisation
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole

Also Published As

Publication number Publication date
US7253202B2 (en) 2007-08-07
CA2511021A1 (en) 2004-07-15
AU2003289904B2 (en) 2009-12-10
PL377325A1 (pl) 2006-01-23
AU2003289904A1 (en) 2004-07-22
ZA200505786B (en) 2006-04-26
EP1572685A1 (de) 2005-09-14
ES2280824T3 (es) 2007-09-16
WO2004058746A1 (de) 2004-07-15
US20060167078A1 (en) 2006-07-27
CA2511021C (en) 2012-08-21
DE50306228D1 (de) 2007-02-15
AR042554A1 (es) 2005-06-22
KR20050084438A (ko) 2005-08-26
JP2006512380A (ja) 2006-04-13
EP1572685B1 (de) 2007-01-03
CN1729187A (zh) 2006-02-01
MXPA05006433A (es) 2005-08-19
JP4575167B2 (ja) 2010-11-04
ATE350379T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0409164A (pt) pirazóis substituìdos
BR0317455A (pt) Derivados de pirrol-pirazol substituìdos como inibidores de quinase
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE408601T1 (de) Fredericamycin-derivate
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BR0015026A (pt) Indóis substituìdos para a modulação da atividade de nfkb
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BRPI0513379A (pt) derivados de sulfonamida
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0412130A (pt) compostos tetracìclicos como inibidores de c-met
BRPI0407097A (pt) Antagonista do casr
BRPI0408444A (pt) derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BRPI0407913A (pt) antagonistas receptores de ccr-3

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]